

ANAGENICS

ASX ANNOUNCEMENT

ANAGENICS LIMITED (ASX: AN1) – BUSINESS UPDATE

- **AN1 Completes acquisition of Face Medi Group**
- **Matthew Dudek appointed Company Secretary**
- **Dr Martin Cross resigns as Non-Executive Director**

SYDNEY, Monday 2 October 2023: Anagenics Limited (AN1) is pleased to announce it has completed the acquisition of Australian professional skincare and beauty retailer Face Medi Group as outlined in AN1's announcement dated 22 August 2023.

Key Acquisition Highlights

- Face MediGroup (FMG) is an existing AN1 customer and the acquisition creates a unique professional beauty platform
- 53% increase in AN1's pro-forma revenue providing scale and synergy for further operational efficiencies
- FMG is a fast-growing business (24% FY23 revenue growth) complementing AN1's improving trajectory and drive towards near-term profitability
- FY24 YTD revenue growth +20% vs FY23
- FMG founders rolling significant equity into Anagenics scrip and managing its consolidated beauty vertical

Appointment of Company Secretary

As the company continues to progress its focus to achieve near term profitability, AN1 announces Matthew Dudek (CFO) will absorb the role of Company Secretary effective immediately and is continuing to pursue other profit improvement initiatives.

Director Resignation

In view of continuing focus on profit improvement and cost reduction Dr Martin Cross has offered to resign as a director following the completion of the Company's 2023 Annual General Meeting.

Dr Cross joined the AN1 board in October 2017 and has contributed to the strategic direction of the business in a non-executive director capacity. Martin has been an extremely valuable and supportive Director during his tenure and the Board acknowledges his many contributions over the past 6 years and his valuable industry networks and insights.

At this time, the Board does not intend to replace Dr Cross to retain a board size appropriate for AN1's current scale.

Approved for release by the Board of Directors.

Scott Greasley
CEO
+61 412 308 263
info@anagenics.com

ANAGENICS

Anagenics Limited (ASX: AN1)

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. For further information, please see www.anagenics.com.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Anagenics to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as, amongst other, the availability of resources, regulatory environment, the results of marketing and sales activities and competition.

For personal use only